JP4555685B2 - 肥満およびｃｎｓ障害の処置のための選択的ｄ１／ｄ５レセプターアンタゴニスト - Google Patents

肥満およびｃｎｓ障害の処置のための選択的ｄ１／ｄ５レセプターアンタゴニスト Download PDF

Info

Publication number
JP4555685B2
JP4555685B2 JP2004531584A JP2004531584A JP4555685B2 JP 4555685 B2 JP4555685 B2 JP 4555685B2 JP 2004531584 A JP2004531584 A JP 2004531584A JP 2004531584 A JP2004531584 A JP 2004531584A JP 4555685 B2 JP4555685 B2 JP 4555685B2
Authority
JP
Japan
Prior art keywords
alkyl
compound
hydrogen
aryl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004531584A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006501244A (ja
JP2006501244A5 (enExample
Inventor
ウェン−リアン ウ，
デュアン エー． バーネット，
ウィリアム ジェイ． グリーンリー，
サヴァラクラム ケイ． サシクマー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2006501244A publication Critical patent/JP2006501244A/ja
Publication of JP2006501244A5 publication Critical patent/JP2006501244A5/ja
Application granted granted Critical
Publication of JP4555685B2 publication Critical patent/JP4555685B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2004531584A 2002-08-29 2003-08-27 肥満およびｃｎｓ障害の処置のための選択的ｄ１／ｄ５レセプターアンタゴニスト Expired - Fee Related JP4555685B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40685602P 2002-08-29 2002-08-29
PCT/US2003/026878 WO2004020442A1 (en) 2002-08-29 2003-08-27 Selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders

Publications (3)

Publication Number Publication Date
JP2006501244A JP2006501244A (ja) 2006-01-12
JP2006501244A5 JP2006501244A5 (enExample) 2006-08-31
JP4555685B2 true JP4555685B2 (ja) 2010-10-06

Family

ID=31978370

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004531584A Expired - Fee Related JP4555685B2 (ja) 2002-08-29 2003-08-27 肥満およびｃｎｓ障害の処置のための選択的ｄ１／ｄ５レセプターアンタゴニスト

Country Status (11)

Country Link
US (1) US7211574B2 (enExample)
EP (1) EP1537115B1 (enExample)
JP (1) JP4555685B2 (enExample)
CN (1) CN1688584A (enExample)
AT (1) ATE396996T1 (enExample)
AU (1) AU2003262926A1 (enExample)
CA (1) CA2495879C (enExample)
DE (1) DE60321354D1 (enExample)
ES (1) ES2308016T3 (enExample)
MX (1) MXPA05002249A (enExample)
WO (1) WO2004020442A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1823059A (zh) * 2003-05-22 2006-08-23 先灵公司 作为治疗肥胖和CNS疾病的选择性D<sub>1</sub>/D<sub>5</sub>受体拮抗剂的5－H－苯并[D]萘并[2,1－B]氮杂䓬衍生物
WO2025194153A1 (en) 2024-03-15 2025-09-18 Emalex Biosciences, Inc. Pharmaceutical dosage forms and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4973586A (en) * 1986-01-16 1990-11-27 Schering Corporation Fused benzazepines, compositions of, and medical use thereof
WO1987004430A2 (en) * 1986-01-16 1987-07-30 Schering Corporation Fused benzazepines
ATE78467T1 (de) * 1987-07-15 1992-08-15 Schering Corp Kondensierte benzazepine.
DK325188D0 (da) * 1988-06-15 1988-06-15 Novo Industri As Hidtil ukendte benzazepinderivater
WO2003006466A1 (en) * 2001-07-13 2003-01-23 Pharmacia & Upjohn Company Hexahydroazepino (4, 5-g) indoles and indolines as 5-ht receptor ligands

Also Published As

Publication number Publication date
AU2003262926A1 (en) 2004-03-19
CA2495879C (en) 2011-04-26
JP2006501244A (ja) 2006-01-12
CN1688584A (zh) 2005-10-26
DE60321354D1 (de) 2008-07-10
CA2495879A1 (en) 2004-03-11
US7211574B2 (en) 2007-05-01
US20040058906A1 (en) 2004-03-25
WO2004020442A1 (en) 2004-03-11
ES2308016T3 (es) 2008-12-01
MXPA05002249A (es) 2005-06-08
EP1537115A1 (en) 2005-06-08
EP1537115B1 (en) 2008-05-28
ATE396996T1 (de) 2008-06-15

Similar Documents

Publication Publication Date Title
EP2766358B1 (en) Novel oxazine derivatives and their use in the treatment of disease
US9388179B2 (en) N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels
US9624208B2 (en) Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
US20070142369A1 (en) Combination of an H3 antagonist/inverse agonist and an appetite suppressant
JP5746703B2 (ja) α７ｎＡＣｈＲ調節因子としてのインドール及びアザインドール
EP3307067B1 (en) Aminopyrazine compounds with a2a antagonist properties
JP2006516640A (ja) 新規アリールピペラジニル化合物
EP3390374A1 (en) Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
WO2009068246A2 (en) Methods of treating obesity and metabolic disorders
JP2005507918A (ja) 肥満治療用のｍｃｈアンタゴニスト
CN109862893B (zh) 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
JP4619413B2 (ja) 肥満および関連障害の処置のための選択的メラニン濃縮ホルモンレセプターアンタゴニストとしての二環式化合物
JP2008543782A (ja) ５−ｈｔ１ａ受容体のピペラジン−ピペリジンアンタゴニストおよびアゴニスト
JP6542236B2 (ja) 有機化合物
JP2002525373A (ja) ２−ピペラジノアルキルアミノベンゾアゾール誘導体：ドーパミン受容体サブタイプ特殊リガンド
JP4555685B2 (ja) 肥満およびｃｎｓ障害の処置のための選択的ｄ１／ｄ５レセプターアンタゴニスト
JP6783793B2 (ja) インドール誘導体
JP2006501244A5 (enExample)
JP2006526021A5 (enExample)
JP2006526021A (ja) 肥満およびｃｎｓ障害を治療する選択的ｄ１／ｄ５レセプタアンタゴニストとしての５ｈ−ベンゾ［ｄ］ナフト［２，１−ｂ］アゼピン誘導体
JP2023507188A (ja) 白金耐性がんの治療に有用な１ｈ－ピラゾロ［３，４－ｄ］ピリミジン化合物
JP2007516290A (ja) 肥満およびｃｎｓ障害の処置のための選択的ｄ１ドーパミンレセプターアンタゴニストとしての置換ｎ−アリールアミジン
JP2022523562A (ja) 神経変性疾患および癌の治療のための化合物
KR100535324B1 (ko) 피페리딘유도체
KR101459720B1 (ko) 세로토닌 5-ＨＴ6 저해 활성을 갖는 5-설포닐아미노-5,6-다이하이드로-1Ｈ-피라졸로[3,4-ｃ]피리딘-7(4Ｈ)-온 화합물

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20060714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100309

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100506

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100705

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100716

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130723

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees